Evidence map›Paper›PMID 36070365›Full record

ReviewScience translational medicine2022

Advances toward transformative therapies for tendon diseases.

Benjamin R Freedman, David J Mooney, Eckhard Weber

Open access · greenAbstract readReview
In one paragraph

Review in Science translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
6.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Achilles tendinopathy.Nature reviews. Disease primers · 2025
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Applications of functionally-adapted hydrogels in tendon repair.Frontiers in bioengineering and biotechnology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Benjamin R FreedmanJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USA.ORCID 0000-0001-9406-773X
David J MooneyJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USA.ORCID 0000-0001-6299-1194
Eckhard WeberNovartis Pharma AG, Basel CH 4056, Switzerland.ORCID 0000-0002-1762-005X
Harvard University · USNovartis (Switzerland) · CH

Funding

Multifunctional tough adhesive hydrogels to recruit, expand, and deliver tendoncells during aging and injuryK99AG065495 · NIA · HARVARD UNIVERSITY · PI FREEDMAN, BENJAMIN ROSS · 2020 to 2022
$341k
NIA NIH HHS K99 AG065495
6 · The paper itself

Abstract

Approved therapies for tendon diseases have not yet changed the clinical practice of symptomatic pain treatment and physiotherapy. This review article summarizes advances in the development of novel drugs, biologic products, and biomaterial therapies for tendon diseases with perspectives for translation of integrated therapies. Shifting from targeting symptom relief toward disease modification and prevention of disease progression may open new avenues for therapies. Deep evidence-based clinical, cellular, and molecular characterization of the underlying pathology of tendon diseases, as well as therapeutic delivery optimization and establishment of multidiscipline interorganizational collaboration platforms, may accelerate the discovery and translation of transformative therapies for tendon diseases.

Indexed as

Tendons

Identifiers

PMID36070365
PMCPMC11041812
OpenAlexW4294884782

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.